Sign in

    Annabel Sammy

    Managing Director and Senior Analyst in Healthcare at Stifel

    Annabel Samimy is a Managing Director and Senior Analyst in Healthcare at Stifel, specializing in biopharmaceuticals with coverage of both specialty pharmaceutical and biotechnology companies. She has been recognized for her performance with honors such as The Wall Street Journal’s 'Best on the Street' Analysts Survey and has ranked three times in the Financial Times/StarMine Awards, placing twice as #2 for earnings estimates and once as #3 for stock picking. Annabel began her career at UBS in structured/project finance before moving to equity research, later joined Thomas Weisel Partners to cover small/mid-cap pharma and biotech, and then transitioned to Stifel in 2010 through their acquisition of Thomas Weisel Partners. She holds a degree in International Relations and Economics from Tufts University and an MA in International Finance and International Affairs from Columbia University’s School of International and Public Affairs.

    Annabel Sammy's questions to Evofem Biosciences (EVFM) leadership

    Annabel Sammy's questions to Evofem Biosciences (EVFM) leadership • Q4 2021

    Question

    On behalf of Annabel Sammy of Stifel, a question was asked regarding the level of copay assistance included in Q4 2021 results versus Q3. A second question probed whether the company has observed tangible benefits in access or prescription trends in early 2022 from the new zero-dollar copay guidance.

    Answer

    CFO Jay File explained that while the copay program was active for most of Q4, accounting for its January discontinuation positively impacted the gross-to-net calculation in December, with Q1 2022 being the first full quarter to reflect the change. CEO Saundra Pelletier confirmed that they have already seen a positive lift in access as many small and mid-sized plans have adopted the new coverage ahead of the mandate.

    Ask Fintool Equity Research AI